http://www.xconomy.com/seattle/2009/05/08/cell-therapeutics-cash-to-last-to-august/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 03:54:18 +0000 hourly 1 http://wordpress.org/?v=3.0.4 http://www.xconomy.com/seattle/2009/05/08/cell-therapeutics-cash-to-last-to-august/comment-page-1/#comment-65491 Cell For Cash News | Most Popular Searches - webmastereye.net Mon, 15 Jun 2009 04:03:00 +0000 http://www.xconomy.com/?p=23948#comment-65491 [...] Cell Therapeutics Cash To Last Into August | XconomyCell Therapeutics has really been living life on the edge. The Seattle biotech company (NASDAQ: [[ticker:CTIC]]) had just $700000 in cash left at the end of. Read more [...] [...] Cell Therapeutics Cash To Last Into August | XconomyCell Therapeutics has really been living life on the edge. The Seattle biotech company (NASDAQ: [[ticker:CTIC]]) had just $700000 in cash left at the end of. Read more [...]

]]> http://www.xconomy.com/seattle/2009/05/08/cell-therapeutics-cash-to-last-to-august/comment-page-1/#comment-57570 David S. Tue, 12 May 2009 16:17:43 +0000 http://www.xconomy.com/?p=23948#comment-57570 There are a few key points that this article are missing. 1) Dr. Bianco stated before and recently in the Webcast that the patients with the cardiac issues had prior issues due to previous treatments from other cancer therapies. 2) There is not another drug in Trials or Existence that has the results of Pixantrone Phase III Studies. Key data points are, "complete remission", "tumors completely gone in 20% of patients treated", and "results are 47% faster than any previous category drug", and "all patients studied survived." There are a few key points that this article are missing. 1) Dr. Bianco stated before and recently in the Webcast that the patients with the cardiac issues had prior issues due to previous treatments from other cancer therapies. 2) There is not another drug in Trials or Existence that has the results of Pixantrone Phase III Studies. Key data points are, “complete remission”, “tumors completely gone in 20% of patients treated”, and “results are 47% faster than any previous category drug”, and “all patients studied survived.”

]]> http://www.xconomy.com/seattle/2009/05/08/cell-therapeutics-cash-to-last-to-august/comment-page-1/#comment-56940 News, Money and Drugs for Friday, May 8, 2009 | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Research, Humor and Updates on the Latest Events in Biotech and Pharma - Unique, Insightful, Truthful, Sometimes Sneaky Sat, 09 May 2009 02:01:20 +0000 http://www.xconomy.com/?p=23948#comment-56940 [...] Cell Therapeutics only has cash to last to August, Pixantrone cardiac issues still a concern. [Xconomy] [...] [...] Cell Therapeutics only has cash to last to August, Pixantrone cardiac issues still a concern. [Xconomy] [...]

]]> http://www.xconomy.com/seattle/2009/05/08/cell-therapeutics-cash-to-last-to-august/comment-page-1/#comment-56878 Satelec Phone | Cell Therapeutics Cash To Last Into August | Xconomy Fri, 08 May 2009 20:40:23 +0000 http://www.xconomy.com/?p=23948#comment-56878 [...] more from the original source:  Cell Therapeutics Cash To Last Into August | Xconomy Thank you for reading this post. You can now Leave A Comment (0) or Leave A [...] [...] more from the original source:  Cell Therapeutics Cash To Last Into August | Xconomy Thank you for reading this post. You can now Leave A Comment (0) or Leave A [...]

]]> http://www.xconomy.com/seattle/2009/05/08/cell-therapeutics-cash-to-last-to-august/comment-page-1/#comment-56835 Dan Eramian Fri, 08 May 2009 17:06:51 +0000 http://www.xconomy.com/?p=23948#comment-56835 Total gross proceeds from the single investor were in fact $23.8 M, not just $15 M...obviously the company could raise further capital...share price has risen over 2,000% since March 2. Total gross proceeds from the single investor were in fact $23.8 M, not just $15 M…obviously the company could raise further capital…share price has risen over 2,000% since March 2.

]]>